Biogen [BIIB] vs Johnson & Johnson [JNJ] Detailed Stock Comparison

Biogen

NASDAQ
Loading...

Johnson & Johnson

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Biogen wins in 12 metrics, Johnson & Johnson wins in 7 metrics, with 0 ties. Biogen appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricBiogenJohnson & JohnsonBetter
P/E Ratio (TTM)15.3020.20Biogen
Price-to-Book Ratio1.335.79Biogen
Debt-to-Equity Ratio37.4064.69Biogen
PEG Ratio1.921.12Johnson & Johnson
EV/EBITDA8.4716.07Biogen
Profit Margin (TTM)15.31%25.00%Johnson & Johnson
Operating Margin (TTM)34.61%28.91%Biogen
EBITDA Margin (TTM)34.61%28.91%Biogen
Return on Equity9.13%30.21%Johnson & Johnson
Return on Assets (TTM)5.62%7.61%Johnson & Johnson
Free Cash Flow (TTM)$2.52B$18.06BJohnson & Johnson
Dividend YieldN/A2.47%N/A
1-Year Return-18.22%16.54%Johnson & Johnson
Price-to-Sales Ratio (TTM)2.345.01Biogen
Enterprise Value$27.28B$486.19BJohnson & Johnson
EV/Revenue Ratio2.735.37Biogen
Gross Profit Margin (TTM)77.13%67.87%Biogen
Revenue per Share (TTM)$68$38Biogen
Earnings per Share (Diluted)$10.45$9.34Biogen
Beta (Stock Volatility)0.130.39Biogen
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Biogen vs Johnson & Johnson Stock Performance Analysis

Loading Price Chart...

Biogen
Johnson & Johnson
Biogen Stock Overview | Johnson & Johnson Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Biogen-3.65%11.21%8.98%18.38%29.25%2.70%
Johnson & Johnson-0.25%3.60%5.63%21.18%24.92%30.65%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Biogen-18.22%-41.79%-44.98%-43.44%167.17%305.18%
Johnson & Johnson16.54%14.41%27.05%91.53%195.99%195.38%

News Based Sentiment: Biogen vs Johnson & Johnson

Biogen

News based Sentiment: POSITIVE

October proved to be a pivotal month for Biogen, driven by the promising Phase III results for Lecanemab, a potential blockbuster Alzheimer's drug. This, combined with strategic partnerships, regulatory approvals, and strong financial performance, significantly strengthens the company's long-term outlook and justifies a positive investment sentiment.

View Biogen News Sentiment Analysis

Johnson & Johnson

News based Sentiment: POSITIVE

October was a strong month for Johnson & Johnson, driven by multiple analyst upgrades, positive financial guidance, and promising clinical trial data. The stock's impressive performance and increased institutional interest suggest a positive shift in investor sentiment and a strengthening investment case.

View Johnson & Johnson News Sentiment Analysis

Performance & Financial Health Analysis: Biogen vs Johnson & Johnson

MetricBIIBJNJ
Market Information
Market Cap i$23.44B$454.31B
Market Cap CategoryLarge capMega cap
10 Day Avg. Volume i1,927,0008,896,250
90 Day Avg. Volume i1,761,4538,482,823
Last Close$154.05$188.16
52 Week Range$110.04 - $194.13$140.68 - $189.91
% from 52W High-20.65%-0.92%
All-Time High$480.18 (Mar 16, 2015)$189.91 (Oct 06, 2025)
% from All-Time High-67.92%-0.92%
Growth Metrics
Quarterly Revenue Growth0.07%0.06%
Quarterly Earnings Growth0.09%0.18%
Financial Health
Profit Margin (TTM) i0.15%0.25%
Operating Margin (TTM) i0.35%0.29%
Return on Equity (TTM) i0.09%0.30%
Debt to Equity (MRQ) i37.4064.69
Cash & Liquidity
Book Value per Share (MRQ)$120.29$32.61
Cash per Share (MRQ)$18.82$7.84
Operating Cash Flow (TTM) i$2.12B$23.03B
Levered Free Cash Flow (TTM) i$2.27B$11.08B
Dividends
Last 12-Month Dividend Yield iN/A2.47%
Last 12-Month Dividend iN/A$3.72

Valuation & Enterprise Metrics Analysis: Biogen vs Johnson & Johnson

MetricBIIBJNJ
Price Ratios
P/E Ratio (TTM) i15.3020.20
Forward P/E i9.6017.80
PEG Ratio i1.921.12
Price to Sales (TTM) i2.345.01
Price to Book (MRQ) i1.335.79
Market Capitalization
Market Capitalization i$23.44B$454.31B
Enterprise Value i$27.28B$486.19B
Enterprise Value Metrics
Enterprise to Revenue i2.735.37
Enterprise to EBITDA i8.4716.07
Risk & Other Metrics
Beta i0.130.39
Book Value per Share (MRQ) i$120.29$32.61

Financial Statements Comparison: Biogen vs Johnson & Johnson

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)BIIBJNJ
Revenue/Sales i$2.43B$23.74B
Cost of Goods Sold i$629.30M$7.63B
Gross Profit i$1.80B$16.12B
Research & Development i$434.10M$3.52B
Operating Income (EBIT) i$625.20M$6.81B
EBITDA i$831.80M$9.21B
Pre-Tax Income i$311.20M$6.49B
Income Tax i$70.70M$954.00M
Net Income (Profit) i$240.50M$5.54B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)BIIBJNJ
Cash & Equivalents i$2.60B$38.47B
Total Current Assets i$7.63B$71.55B
Total Current Liabilities i$5.30B$56.90B
Long-Term Debt i$4.87B$38.36B
Total Shareholders Equity i$16.98B$78.11B
Retained Earnings i$19.50BN/A
Property, Plant & Equipment i$6.22BN/A

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)BIIBJNJ
Operating Cash Flow i$518.90M$6.35B
Capital Expenditures i$-37.10M$-795.00M
Free Cash Flow i$212.20M$3.37B
Debt Repayment i$0$-2.87B
Common Stock Repurchase iN/A$-2.13B

Short Interest & Institutional Ownership Analysis

MetricBIIBJNJ
Shares Short i5.13M22.05M
Short Ratio i3.352.84
Short % of Float i0.05%0.01%
Average Daily Volume (10 Day) i1,927,0008,896,250
Average Daily Volume (90 Day) i1,761,4538,482,823
Shares Outstanding i145.72M2.41B
Float Shares i146.23M2.40B
% Held by Insiders i0.00%0.00%
% Held by Institutions i0.93%0.74%

Dividend Analysis & Yield Comparison: Biogen vs Johnson & Johnson

MetricBIIBJNJ
Last 12-Month Dividend iN/A$3.72
Last 12-Month Dividend Yield iN/A2.47%
3-Year Avg Annual Dividend iN/A$3.97
3-Year Avg Dividend Yield iN/A0.75%
3-Year Total Dividends iN/A$11.92
Ex-Dividend DateN/AFeb 18, 2025